ORYZON to present data from ETHERAL Phase IIa trial at the 2019 Alzheimer's Association International Conference in Los Angeles

Safety data from the first 90 patients will be presented
Parametric evolution of the first (blinded) 33 patients that have been treated for 6 months will also be discussed

Oryzon Genomics, S.A.(ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the company will present data from the ongoing Phase IIaclinical trial with vafidemstatin Alzheimer’s disease (AD) named ETHERAL (Epigenetic THERapy in ALzheimer’s Disease) at the 2019 Alzheimer's Association International Conference (AAIC-2019) to be held in Los Angeles (USA) on July 14-18.

Dr.Roger Bullock, Oryzon’s Medical Director, and Dr.Michael Ropacki,Oryzon’s Vice-President of Clinical Development, will attend the Conference. Dr. Bullock will present a written communication in the form of a Poster entitled “P#31419. Safety Evaluation of Vafidemstat on Mild to Moderate Alzheimer’s Subjects”at the session “Therapeutics: Clinical”to be held on Monday, July 15, 2019,9:30 AM -4:15 PM, at the Los Angeles Convention Center, South Hall GH. Safety data from the first 90 patients will be presented and the evolution of some relevant (blinded) functional parameters on the 33 first patients that have finished the first 6 months of treatment will be also discussed.

For more information about the Conference see the website https://www.alz.org/aaic/overview.asp

The ongoing ETHERAL Phase II as tudy is being conducted in 17 European hospitals in UK, France and Spain and 3 additional sites in the US. It is a randomised, double-blind, placebo-controlled, 3-arm, 24 weeks parallel-group study to evaluate the safety, tolerabilityand preliminary efficacy of vafidemstat in patients with mild-to-moderate AD. Secondary end points include measures of cognition, function and behavior. Finally, several traditional and novel CSF biomarkers are also measured. The European arm of the study plans to enroll up to 125 patients, with more than 100 patients already randomized by end ofMay. The US arm of the trial plans to enroll up to 30 patients, to complete a minimum of 150 patients on the aggregate. The company has received a grant of $1.5 millionfrom the Alzheimer’s Drug Discovery Foundation (ADDF) to support theUS-arm of ETHERAL clinical trial.